WAVE Life Sciences
733 Concord Avenue
Cambridge
Massachusetts
02138
United States
Tel: 1-617-949-2900
Fax: 1-617-949-2901
Website: http://wavelifesciences.com/
Email: info@wavelifesci.com
About WAVE Life Sciences
WAVE Life Sciences is a preclinical genetic medicine company focused on advancing first-in-class or best-in-class stereopure nucleic acid therapies for patients impacted by rare diseases. We are utilizing our innovative and proprietary synthetic chemistry platform to design and develop nucleic acid therapeutics that precisely target the underlying cause of rare genetic diseases, with a goal of delivering new and exceptional treatment options for patients. Given the versatility of our chemistry, WAVE’s pipeline spans multiple oligonucleotide modalities including antisense, exon-skipping and single-stranded RNAi, potentially enabling us to address a broad range of therapeutic areas and diseases.
CLINICAL TRIAL:
Please click here for clinical trial information.
FOLLOW WAVE LIFE SCIENCES:
Tweets by Wave Life Sciences
67 articles with WAVE Life Sciences
-
WAVE Life Sciences Reports First Quarter 2017 Financial Results And Provides Business Update
5/10/2017
-
WAVE Life Sciences Prices Public Offering Of 4,166,667 Ordinary Shares
4/12/2017
-
WAVE Life Sciences Announces Proposed Public Offering Of Ordinary Shares
4/12/2017
-
WAVE Life Sciences Reports Fourth Quarter And Full-Year 2016 Financial Results And Provides Business Update
3/16/2017
-
nLife Therapeutics Enters Research Collaboration With WAVE Life Sciences To Explore Targeting Of Nucleic Acids To Specific Cell-Types In The Central Nervous System
3/3/2017
-
WAVE Life Sciences 2017 Pipeline Update
1/9/2017
-
WAVE Life Sciences Reports Third Quarter 2016 Financial Results And Provides Business Update
11/10/2016
-
WAVE Life Sciences Appoints Christian Henry To Its Board Of Directors
11/10/2016
-
WAVE Life Sciences To Present At The Leerink Partners Rare Disease & Immuno-Oncology Roundtable
9/14/2016
-
WAVE Life Sciences Taps Former Shire Exec as New CFO
8/17/2016
-
WAVE Life Sciences Reports Second Quarter 2016 Financial Results And Provides Business Update
8/16/2016
-
WAVE Life Sciences Appoints Dr. Michael Panzara As Head Of Neurology Franchise
7/12/2016
-
WAVE Life Sciences Added To The Russell 2000 Index
6/28/2016
-
WAVE Life Sciences Receives Orphan Drug Designation From FDA For Its Lead Candidate Designed To Treat Huntington’s Disease
6/21/2016
-
WAVE Life Sciences To Present At The JMP Securities Life Sciences Conference
6/15/2016
-
WAVE Life Sciences To Present At The Jefferies 2016 Healthcare Conference
6/1/2016
-
WAVE Life Sciences Reports First Quarter 2016 Financial Results And Provides Business Update
5/17/2016
-
WAVE Life Sciences To Advance Next-Generation Nucleic Acid Therapies To Address Unmet Need In Duchenne Muscular Dystrophy
5/9/2016
-
Pfizer Turns to WAVE Life Sciences for Drug Discovery in Deal Worth $911 Million
5/6/2016
-
WAVE Life Sciences To Present At The Deutsche Bank 41st Annual Health Care Conference
5/2/2016